

Edgar Filing: ATRIX LABORATORIES INC - Form 8-K

ATRIX LABORATORIES INC  
Form 8-K  
June 20, 2001

1

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

April 4, 2001

-----  
(Date of earliest event reported)

ATRIX LABORATORIES, INC.

-----  
(Exact name of Registrant as specified in its charter)

DELAWARE

0-18231

84-1043826

-----  
(State or Other Jurisdiction  
of Incorporation)

-----  
(Commission File No.)

-----  
(IRS Employer Identification No.)

2579 MIDPOINT DRIVE, FORT COLLINS, COLORADO 80525  
(Address of principal executive offices, including zip code)

(970) 482-5868

-----  
(Registrant's telephone number, including area code)

2

Item 5. Other Events.

On April 4, 2001, Atrix Laboratories, Inc. (the "Company") entered into definitive agreements with MediGene Aktiengesellschaft ("MediGene") granting MediGene the exclusive right to market in Europe the Company's Leuprogel(TM) 1-, 3-, 4- and 6- month products--a leuprolide acetate product for subcutaneous depot injection for the treatment of advanced prostate cancer. In connection with the transaction, the Company and MediGene entered into a Stock Purchase Agreement and a Collaboration, License and Supply Agreement (the "Collaboration Agreement").

The Collaboration Agreement is attached hereto as Exhibit 99.1 and the Stock Purchase Agreement is attached hereto as Exhibit 99.2.

Edgar Filing: ATRIX LABORATORIES INC - Form 8-K

Item 7. Exhibits.

- 99.1\*\* Collaboration, License and Supply Agreement, dated as of April 4, 2001, by and between the Company and MediGene.
- 99.2\*\* Stock Purchase Agreement, dated as of April 4, 2001, by and between the Company and MediGene.

-----  
\*\* Confidential treatment requested.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATRIX LABORATORIES, INC.

By: /s/ Brian G. Richmond

-----  
Brian G. Richmond  
Chief Financial Officer

Date: June 14, 2001

4

EXHIBIT INDEX

EXHIBIT NUMBER -----	DESCRIPTION -----
99.1**	Collaboration, License and Supply Agreement, dated as of April 4, 2001, by and between the Company and MediGene.
99.2**	Stock Purchase Agreement, dated as of April 4, 2001, by and between the Company and MediGene.

THE SYMBOL "[\*\*]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

-----  
\*\* Confidential treatment requested.